Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products.
Shandong Xinhua Pharmaceutical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$3.78|
|52 Week High||HK$3.40|
|52 Week Low||HK$5.70|
|1 Month Change||-0.26%|
|3 Month Change||-5.03%|
|1 Year Change||-4.30%|
|3 Year Change||-5.03%|
|5 Year Change||-14.84%|
|Change since IPO||85.43%|
Recent News & Updates
Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
If you want to know who really controls Shandong Xinhua Pharmaceutical Company Limited ( HKG:719 ), then you'll have to...
Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
|719||HK Pharmaceuticals||HK Market|
Return vs Industry: 719 exceeded the Hong Kong Pharmaceuticals industry which returned -13.7% over the past year.
Return vs Market: 719 underperformed the Hong Kong Market which returned 5.6% over the past year.
Stable Share Price: 719 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 719's weekly volatility (3%) has been stable over the past year.
About the Company
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical Bulk Drugs, Preparations, and Chemical Intermediates and Other products. It offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for central nervous system diseases; and other drugs under the brand of Xinhua.
Is Shandong Xinhua Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 719 (HK$3.78) is trading below our estimate of fair value (HK$4.18)
Significantly Below Fair Value: 719 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 719 is good value based on its PE Ratio (5.6x) compared to the Hong Kong Pharmaceuticals industry average (9.7x).
PE vs Market: 719 is good value based on its PE Ratio (5.6x) compared to the Hong Kong market (9.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 719's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 719 is good value based on its PB Ratio (0.6x) compared to the HK Pharmaceuticals industry average (1.1x).
How is Shandong Xinhua Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shandong Xinhua Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Shandong Xinhua Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 719 has high quality earnings.
Growing Profit Margin: 719's current net profit margins (5.6%) are higher than last year (5.6%).
Past Earnings Growth Analysis
Earnings Trend: 719's earnings have grown by 19.8% per year over the past 5 years.
Accelerating Growth: 719's earnings growth over the past year (9.1%) is below its 5-year average (19.8% per year).
Earnings vs Industry: 719 earnings growth over the past year (9.1%) underperformed the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 719's Return on Equity (10.5%) is considered low.
How is Shandong Xinhua Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 719's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥2.5B).
Long Term Liabilities: 719's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 719's debt to equity ratio (48%) is considered high.
Reducing Debt: 719's debt to equity ratio has reduced from 67.9% to 48% over the past 5 years.
Debt Coverage: 719's debt is well covered by operating cash flow (22.7%).
Interest Coverage: 719's interest payments on its debt are well covered by EBIT (12.3x coverage).
What is Shandong Xinhua Pharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 719's dividend (4.78%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.29%).
High Dividend: 719's dividend (4.78%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.87%).
Stability and Growth of Payments
Stable Dividend: 719's dividend payments have been volatile in the past 10 years.
Growing Dividend: 719's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (26.6%), 719's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Deping Du (51 yo)
Mr. Deping Du serves as the General Manager at Shandong Xinhua Pharmaceutical Co. Ltd. Mr. Du served as Deputy General Manager of Shandong Xinhua Pharmaceutical Co. Ltd. since December 22, 2008.He is a Se...
CEO Compensation Analysis
Compensation vs Market: Deping's total compensation ($USD175.25K) is below average for companies of similar size in the Hong Kong market ($USD422.75K).
Compensation vs Earnings: Deping's compensation has been consistent with company performance over the past year.
Experienced Management: 719's management team is seasoned and experienced (12.8 years average tenure).
Experienced Board: 719's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Shandong Xinhua Pharmaceutical Company Limited's employee growth, exchange listings and data sources
- Name: Shandong Xinhua Pharmaceutical Company Limited
- Ticker: 719
- Exchange: SEHK
- Founded: 1943
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$5.007b
- Shares outstanding: 627.37m
- Website: https://www.xhzy.com
Number of Employees
- Shandong Xinhua Pharmaceutical Company Limited
- Chemical Industry Area
- Zibo Hi-tech Industry Development Zone
- Shandong Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 10:05|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.